目的 對臨床上常用、經(jīng)濟(jì)有效的口服鈣拮抗劑降壓藥進(jìn)行藥物經(jīng)濟(jì)學(xué)評價(jià)，為合理用藥提供借鑒。方法 采用回顧性文獻(xiàn)計(jì)量分析的方法，檢索中英文數(shù)據(jù)庫中2003-2015年發(fā)表的與鈣拮抗劑降壓藥相關(guān)的藥物經(jīng)濟(jì)學(xué)評價(jià)文獻(xiàn)，利用納入排除標(biāo)準(zhǔn)篩選后，對其方法學(xué)和質(zhì)量進(jìn)行評述。結(jié)果 以國家統(tǒng)計(jì)局報(bào)告的2014年我國人均GDP為外部參考值，將硝苯地平作為對照藥品，非洛地平、氨氯地平、硝苯地平緩釋片、硝苯地平控釋片的增量成本效果比值均在451~8 543元，均小于人均GDP。結(jié)論 《中國高血壓防治指南》推薦的藥物、但《國家基本藥物目錄》（2012版）中尚未收載的硝苯地平控釋片、左旋氨氯地平、非洛地平均具有一定經(jīng)濟(jì)性。

Objective To provide reference for the clinical treatment of anti-hypertensive drugs associated with calcium antagonists by methods of retrospective analysis of literature. Methods In this study, the literature on the economic evaluation of the drugs associated with calcium antagonists during the period from 2003 to 2015 were searched, and then the methods and quality of the literatures were reviewed. Results The incremental cost effectiveness ratio of Felodipine, Amlodipine, Nifedipine sustained release tablets, and Nifedipine controlled release tablets were between 451 to 8 543 yuan and less than per capita GDP in 2014 with Nifedipine controlled release tablets as the control drug. Conclusion Nifedipine controlled release tablets, amlodipine, and Felodipine recommended by Chinese Hypertension Prevention Guide are economical, but have not yet been received by the National Essential Drug List (2012 Edition).

中國博士后科學(xué)基金資助項(xiàng)目（2014M561196）；天津醫(yī)科大學(xué)科學(xué)基金項(xiàng)目（2014KYRQ04）